Insider transactions

EDGAR

Adicet Bio, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
3 transactions, 223,596 shares
Sum of shares × price per share: 1,603,934.13
Open-market sales (code S)
4 transactions, 104,658 shares
Sum of shares × price per share: 674,847.06

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–27 of 27

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-05 Filed 2026-08-07Klickstein Lloyd Director · Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (18,300) — exercise price 9.16
Acquired (A)18,3000.00
0

Derived: shares × price per share. Exact value 0.00.

18,300Direct (D) No
F1
  • F1 1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates.
Open filing 0001776004-26-000003 Read from the filing’s XML Dispute this row
2026-06-21 Filed 2026-06-23DUBIN STEVE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,200) — exercise price 8.10
Acquired (A)4,2000—4,200Direct (D) No
F1
  • F1 These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Open filing 0001265123-26-000001 Read from the filing’s XML Dispute this row
2026-06-21 Filed 2026-06-23Peng Katie Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,200) — exercise price 8.10
Acquired (A)4,2000—4,200Direct (D) No
F1
  • F1 These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Open filing 0001983850-26-000001 Read from the filing’s XML Dispute this row
2026-06-21 Filed 2026-06-23Sinclair Andrew Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,200) — exercise price 8.10
Acquired (A)4,2000—4,200Direct (D) No
F1
  • F1 These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Open filing 0001762451-26-000002 Read from the filing’s XML Dispute this row
2026-06-21 Filed 2026-06-23Grissinger Michael Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,200) — exercise price 8.10
Acquired (A)4,2000—4,200Direct (D) No
F1
  • F1 These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Open filing 0001757601-26-000002 Read from the filing’s XML Dispute this row
2026-06-21 Filed 2026-06-23Klickstein Lloyd Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,200) — exercise price 8.10
Acquired (A)4,2000—4,200Direct (D) No
F1
  • F1 These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Open filing 0001776004-26-000001 Read from the filing’s XML Dispute this row
2026-06-21 Filed 2026-06-23Chodakewitz Jeffrey Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,200) — exercise price 8.10
Acquired (A)4,2000.00
0

Derived: shares × price per share. Exact value 0.00.

4,200Direct (D) No
F1
  • F1 These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Open filing 0001610876-26-000002 Read from the filing’s XML Dispute this row
2026-06-19 Filed 2026-06-23Schor Chen Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (55,000) — exercise price 8.10
Acquired (A)55,0000—55,000Direct (D) No
F1
  • F1 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Open filing 0001340875-26-000007 Read from the filing’s XML Dispute this row
2026-06-19 Filed 2026-06-23Aftab Blake Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (55,000) — exercise price 8.10
Acquired (A)55,0000—55,000Direct (D) No
F1
  • F1 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Open filing 0001886986-26-000004 Read from the filing’s XML Dispute this row
2026-04-27 Filed 2026-04-29RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)250,000——932,624Indirect (I) See footnotesNo
F1, F2, F3
  • F1 On April 27, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 250,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 250,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (the Pre-Funded Warrant).
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000425 Read from the filing’s XML Dispute this row
2026-04-27 Filed 2026-04-29RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
J

Other acquisition or disposition (describe transaction)

Derivative security: Pre-Funded Warrant (Right to Buy) — underlying Common Stock (250,000) — exercise price 0.0001
Acquired (A)250,000——1,402,833Indirect (I) See footnotesNo
F1, F4, F2, F3
  • F1 On April 27, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 250,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 250,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (the Pre-Funded Warrant).
  • F4 The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000425 Read from the filing’s XML Dispute this row
2026-04-08 Filed 2026-04-09ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)32,5236.29
204,569.67

Derived: shares × price per share. Exact value 204569.67.

0Indirect (I) See footnotesNo
F1, F6
  • F1 These securities are held of record by OrbiMed Israel Partners Limited Partnership (OIP). OrbiMed Israel BioFund GP Limited Partnership (OrbiMed BioFund) is the general partner of OIP, and OrbiMed Israel GP Ltd. (OrbiMed Israel GP) is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP.
  • F6 Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row
2026-04-08 Filed 2026-04-09ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)40,4166.52
263,512.32

Derived: shares × price per share. Exact value 263512.32.

0Indirect (I) See footnotesNo
F2, F6
  • F2 These securities are held of record by OrbiMed Israel Partners II, L.P. (OIP II). OrbiMed Israel GP II, L.P. (OrbiMed Israel GP II) is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (OrbiMed Israel II) is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II.
  • F6 Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row
2026-04-07 Filed 2026-04-09ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)29,3196.53
191,453.07

Derived: shares × price per share. Exact value 191453.07.

34,923Indirect (I) See footnotesNo
F1, F6
  • F1 These securities are held of record by OrbiMed Israel Partners Limited Partnership (OIP). OrbiMed Israel BioFund GP Limited Partnership (OrbiMed BioFund) is the general partner of OIP, and OrbiMed Israel GP Ltd. (OrbiMed Israel GP) is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP.
  • F6 Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row
2026-04-07 Filed 2026-04-09ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,4006.38
15,312

Derived: shares × price per share. Exact value 15312.00.

32,523Indirect (I) See footnotesNo
F1, F6
  • F1 These securities are held of record by OrbiMed Israel Partners Limited Partnership (OIP). OrbiMed Israel BioFund GP Limited Partnership (OrbiMed BioFund) is the general partner of OIP, and OrbiMed Israel GP Ltd. (OrbiMed Israel GP) is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP.
  • F6 Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row
2026-03-25 Filed 2026-03-27Aftab Blake Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (72,555) — exercise price 6.81
Acquired (A)72,5550.00
0

Derived: shares × price per share. Exact value 0.00.

72,555Direct (D) No
F1
  • F1 (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Open filing 0001886986-26-000002 Read from the filing’s XML Dispute this row
2026-03-25 Filed 2026-03-27Healey Don Officer: Chief Technology Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (43,361) — exercise price 6.81
Acquired (A)43,3610.00
0

Derived: shares × price per share. Exact value 0.00.

43,361Direct (D) No
F1
  • F1 (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Open filing 0001643067-26-000002 Read from the filing’s XML Dispute this row
2026-03-25 Filed 2026-03-27Maltzman Julia D. Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (72,555) — exercise price 6.81
Acquired (A)72,5550.00
0

Derived: shares × price per share. Exact value 0.00.

72,555Direct (D) No
F1
  • F1 (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Open filing 0002052749-26-000003 Read from the filing’s XML Dispute this row
2026-03-25 Filed 2026-03-27Schor Chen Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (468,555) — exercise price 6.81
Acquired (A)468,5550.00
0

Derived: shares × price per share. Exact value 0.00.

468,555Direct (D) No
F1
  • F1 (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Open filing 0001340875-26-000003 Read from the filing’s XML Dispute this row
2026-03-25 Filed 2026-03-27Harvey Brian Nicholas Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (43,361) — exercise price 6.81
Acquired (A)43,3610.00
0

Derived: shares × price per share. Exact value 0.00.

43,361Direct (D) No
F1
  • F1 (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
Open filing 0001519432-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-04-13RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)74,7517.27
543,439.77

Derived: shares × price per share. Exact value 543439.77.

1,182,624Indirect (I) See footnotesNo
F5, F2, F3
  • F5 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.05 to $7.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000337 Read from the filing’s XML Dispute this row
2026-02-19 Filed 2026-04-13RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)74,2687.21
535,472.28

Derived: shares × price per share. Exact value 535472.28.

1,107,873Indirect (I) See footnotesNo
F4, F2, F3
  • F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.89 to $7.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000337 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-04-13RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)74,5777.04
525,022.08

Derived: shares × price per share. Exact value 525022.08.

1,033,605Indirect (I) See footnotesNo
F1, F2, F3
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.89 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for RA Capital Healthcare Fund, L.P. (the Fund). The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000337 Read from the filing’s XML Dispute this row
2026-01-24 Filed 2026-01-27Harvey Brian Nicholas Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5468.44
4,608.24

Derived: shares × price per share. Exact value 4608.24.

5,145Direct (D) No
F1, F2
  • F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
  • F2 Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.
Open filing 0001193125-26-024746 Read from the filing’s XML Dispute this row
2026-01-24 Filed 2026-01-27Schor Chen Director · Officer: President CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,7558.44
14,812.2

Derived: shares × price per share. Exact value 14812.20.

6,820Direct (D) No
F1, F2
  • F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
  • F2 Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.
Open filing 0001193125-26-024749 Read from the filing’s XML Dispute this row
2026-01-24 Filed 2026-01-27Healey Don Officer: Chief Technology Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5358.44
4,515.4

Derived: shares × price per share. Exact value 4515.40.

3,452Direct (D) No
F1, F2
  • F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
  • F2 Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.
Open filing 0001193125-26-024753 Read from the filing’s XML Dispute this row
2026-01-24 Filed 2026-01-27Aftab Blake Officer: Chief Scientific Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5358.44
4,515.4

Derived: shares × price per share. Exact value 4515.40.

2,981Direct (D) No
F1, F2
  • F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
  • F2 Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.
Open filing 0001193125-26-024755 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 61

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
RA CAPITAL MANAGEMENT, L.P. 932,624 SH6,658,935 dollarsUnchanged Prior quarter: 932,624Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
ORBIMED ADVISORS LLC 844,787 SH6,031,779 dollarsUnchanged Prior quarter: 844,787Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager724,138 SH2,244,828 dollarsHigher by 97,567 Prior quarter: 626,571Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 366,216 SH2,614,782 dollarsHigher by 22,988 Prior quarter: 343,228Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager280,372 SH2,001,856 dollarsLower by 152,366 Prior quarter: 432,738Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager214,841 SH1,533,965 dollarsLower by 51,104 Prior quarter: 265,945Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
Alyeska Investment Group, L.P. 203,799 SH1,455,125 dollarsUnchanged Prior quarter: 203,799Open filing 0001172661-26-005329 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 193,125 SH1,378,913 dollarsLower by 81,250 Prior quarter: 274,375Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Schonfeld Strategic Advisors LLC 188,948 SH1,349,087 dollarsLower by 6,566 Prior quarter: 195,514Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
Stonepine Capital Management, LLC 188,201 SH1,343,755 dollarsLower by 57,317 Prior quarter: 245,518Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
Carlyle Group Inc. Partly reported under another manager184,295 SH1,315,865 dollarsUnchanged Prior quarter: 184,295Open filing 0000898432-26-000769 Filed 2026-11-06 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager170,832 SH1,217 dollarsHigher by 46,000 Prior quarter: 124,832Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
UBS Group AG Partly reported under another manager118,197 SH843,927 dollarsHigher by 88,380 Prior quarter: 29,817Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
DAFNA Capital Management LLC 93,812 SH669,818 dollarsUnchanged Prior quarter: 93,812Open filing 0001389933-26-000010 Filed 2026-11-16 Dispute this row
Trexquant Investment LP Partly reported under another manager89,813 SH641,265 dollarsHigher by 11,811 Prior quarter: 78,002Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 85,959 SH613,747 dollarsUnchanged Prior quarter: 85,959Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager84,847 SH606,163 dollarsLower by 10,787 Prior quarter: 95,634Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
TWO SIGMA INVESTMENTS, LP 72,915 SH520,613 dollarsLower by 23,924 Prior quarter: 96,839Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager69,235 SH494,338 dollarsLower by 10,253 Prior quarter: 79,488Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
Rangeley Capital, LLC 64,000 SH456,960 dollarsHigher by 13,108 Prior quarter: 50,892Open filing 0001892688-26-000185 Filed 2026-11-16 Dispute this row
Burkehill Global Management, LP 62,500 SH446,250 dollarsUnchanged Prior quarter: 62,500Open filing 0001013594-26-001202 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager61,024 SH435,711 dollarsLower by 1,102 Prior quarter: 62,126Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
REGENERON PHARMACEUTICALS, INC. 60,511 SH432,049 dollarsUnchanged Prior quarter: 60,511Open filing 0001104659-26-123321 Filed 2026-11-05 Dispute this row
VANGUARD FIDUCIARY TRUST CO 50,670 SH361,784 dollarsUnchanged Prior quarter: 50,670Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Verdad Advisers, LP 47,546 SH339,478 dollarsHigher by 22,346 Prior quarter: 25,200Open filing 0001420506-26-002833 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager38,138 SH272,305 dollarsHigher by 6,535 Prior quarter: 31,603Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
STATE STREET CORP Partly reported under another manager36,222 SH258,625 dollarsUnchanged Prior quarter: 36,222Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
RBF Capital, LLC 36,082 SH257,625 dollarsLower by 2,500 Prior quarter: 38,582Open filing 0001062993-26-005971 Filed 2026-11-13 Dispute this row
CITADEL ADVISORS LLC Option: Put Partly reported under another manager35,400 SH252,756 dollarsHigher by 12,600 Prior quarter: 22,800Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager25,980 SH185,498 dollarsLower by 44,581 Prior quarter: 70,561Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
PRELUDE CAPITAL MANAGEMENT, LLC 24,862 SH177,515 dollarsHigher by 6,312 Prior quarter: 18,550Open filing 0000945621-26-001415 Filed 2026-11-16 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 23,308 SH166,419 dollarsNot in the prior quarter’s filings read Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
JOHNSON JOHNSON Partly reported under another manager22,779 SH162,642 dollarsUnchanged Prior quarter: 22,779Open filing 0000904454-26-000541 Filed 2026-10-26 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager18,436 SH131,633 dollarsUnchanged Prior quarter: 18,436Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager14,000 SH99,960 dollarsHigher by 3,290 Prior quarter: 10,710Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Engineers Gate Manager LP 12,950 SH92,463 dollarsNot in the prior quarter’s filings read Open filing 0001620220-26-000010 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager12,942 SH92,406 dollarsLower by 7,708 Prior quarter: 20,650Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Vontobel Holding Ltd. Partly reported under another manager12,775 SH91,214 dollarsLower by 1,001 Prior quarter: 13,776Open filing 0001588340-26-000004 Filed 2026-10-16 Dispute this row
OCCUDO QUANTITATIVE STRATEGIES LP 12,310 SH87,893 dollarsLower by 4,326 Prior quarter: 16,636Open filing 0001420506-26-002797 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager10,836 SH77,370 dollarsHigher by 8,545 Prior quarter: 2,291Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
JANE STREET GROUP, LLC Option: Call Partly reported under another manager10,600 SH75,684 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Arax Advisory Partners Partly reported under another manager6,001 SH42,845 dollarsHigher by 1 Prior quarter: 6,000Open filing 0001586767-26-000009 Filed 2026-11-12 Dispute this row
CITIGROUP INC Partly reported under another manager4,721 SH33,708 dollarsNot in the prior quarter’s filings read Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager3,573 SH25,511 dollarsHigher by 3,523 Prior quarter: 50Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
SIMPLEX TRADING, LLC Option: Call 2,800 SH19,992 dollarsHigher by 1,100 Prior quarter: 1,700Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
Vanguard Global Advisers, LLC 2,070 SH14,780 dollarsLower by 3,151 Prior quarter: 5,221Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager1,988 SH14,000 dollarsHigher by 287 Prior quarter: 1,701Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
GROUP ONE TRADING LLC Option: Call 1,100 SH7,854 dollarsNot in the prior quarter’s filings read Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager1,038 SH7,412 dollarsHigher by 761 Prior quarter: 277Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
SIMPLEX TRADING, LLC 934 SH6,668 dollarsLower by 3,880 Prior quarter: 4,814Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • NEXTBio Capital Management LP 157,827 SH
  • Quadrature Capital Ltd 36,193 SH
  • XTX Topco Ltd 24,284 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 19,600 SH
  • Squarepoint Ops LLC 15,254 SH
  • AXQ CAPITAL, LP 10,991 SH
  • Jump Financial, LLC 10,942 SH
  • FMR LLC 6 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Zedek Daniel Clayton Common Stock, $0.0001 par vaue5.4502,309.0010/19/2026 Filed 2026-10-23SCHEDULE 13GOpen filing 0002161951-26-000001 Dispute this row
Zedek Lauren Marie Common Stock, $0.0001 par vaue5.4502,309.0010/19/2026 Filed 2026-10-23SCHEDULE 13GOpen filing 0002161951-26-000001 Dispute this row
Franklin Templeton, Inc. Common Stock, par value $0.0001 per share7.7724,138.0009/30/2026 Filed 2026-10-28SCHEDULE 13G/AAmendment 1Open filing 0000038777-26-000272 Dispute this row
Charles B. Johnson Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-10-28SCHEDULE 13G/AAmendment 1Open filing 0000038777-26-000272 Dispute this row
Rupert H. Johnson, Jr. Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-10-28SCHEDULE 13G/AAmendment 1Open filing 0000038777-26-000272 Dispute this row
Franklin Advisers, Inc. Common Stock, par value $0.0001 per share7.7724,138.0009/30/2026 Filed 2026-10-28SCHEDULE 13G/AAmendment 1Open filing 0000038777-26-000272 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share9.9935,486.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000916 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share9.9935,486.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000916 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share9.9935,486.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000916 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share9.9935,486.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000916 Dispute this row
ORBIMED ADVISORS LLC Common Stock, par value $0.00018.8844,787.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
ORBIMED CAPITAL GP VI LLC Common Stock, par value $0.00012.9280,640.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
ORBIMED CAPITAL GP V LLC Common Stock, par value $0.00015.9564,147.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
OrbiMed Genesis GP LLC Common Stock, par value $0.000100.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
ORBIMED ADVISORS ISRAEL II LTD Common Stock, par value $0.000100.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
ORBIMED ISRAEL GP II, L.P. Common Stock, par value $0.000100.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
ORBIMED ISRAEL GP LTD. Common Stock, par value $0.000100.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP Common Stock, par value $0.000100.0004/08/2026 Filed 2026-04-10SCHEDULE 13D/AAmendment 9Open filing 0000947871-26-000427 Dispute this row
Woodline Partners LP Common Stock, par value $0.0001 per share3.3313,124.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003239 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share12.31,182,624.0002/17/2026 Filed 2026-04-13SCHEDULE 13G/AAmendment 3Open filing 0001346824-26-000105 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share12.31,182,624.0002/17/2026 Filed 2026-04-13SCHEDULE 13G/AAmendment 3Open filing 0001346824-26-000105 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share12.31,182,624.0002/17/2026 Filed 2026-04-13SCHEDULE 13G/AAmendment 3Open filing 0001346824-26-000105 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share12.31,182,624.0002/17/2026 Filed 2026-04-13SCHEDULE 13G/AAmendment 3Open filing 0001346824-26-000105 Dispute this row
Woodline Partners LP Common Stock, par value $0.0001 per share6.5625,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0000902664-26-001061 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share9.9960,237.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000031 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share9.9960,237.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000031 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share9.9960,237.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000031 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share9.9960,237.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000031 Dispute this row
TANG CAPITAL MANAGEMENT, LLC Common Stock, par value $0.0001 per share0.16,158.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001214659-26-002017 Dispute this row
KEVIN TANG Common Stock, par value $0.0001 per share0.16,158.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001214659-26-002017 Dispute this row
TANG CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share00.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001214659-26-002017 Dispute this row
TANG CAPITAL PARTNERS INTERNATIONAL, LP Common Stock, par value $0.0001 per share0.16,158.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001214659-26-002017 Dispute this row
TANG CAPITAL PARTNERS III, INC Common Stock, par value $0.0001 per share0.00.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001214659-26-002017 Dispute this row
TANG CAPITAL PARTNERS IV, INC Common Stock, par value $0.0001 per share0.00.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 4Open filing 0001214659-26-002017 Dispute this row
Franklin Resources, Inc. Common Stock, par value $0.0001 per share6.5626,571.0012/31/2025 Filed 2026-01-29SCHEDULE 13GOpen filing 0000038777-26-000021 Dispute this row
Charles B. Johnson Common Stock, par value $0.0001 per share00.0012/31/2025 Filed 2026-01-29SCHEDULE 13GOpen filing 0000038777-26-000021 Dispute this row
Rupert H. Johnson, Jr. Common Stock, par value $0.0001 per share00.0012/31/2025 Filed 2026-01-29SCHEDULE 13GOpen filing 0000038777-26-000021 Dispute this row
Franklin Advisers, Inc. Common Stock, par value $0.0001 per share6.5626,571.0012/31/2025 Filed 2026-01-29SCHEDULE 13GOpen filing 0000038777-26-000021 Dispute this row
ORBIMED ADVISORS LLC Common Stock, par value $0.00019.614,772,598.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row
ORBIMED CAPITAL GP VI LLC Common Stock, par value $0.00012.94,490,254.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row
ORBIMED CAPITAL GP V LLC Common Stock, par value $0.00015.99,026,359.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row
OrbiMed Genesis GP LLC Common Stock, par value $0.00010.81,255,985.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row
ORBIMED ADVISORS ISRAEL II LTD Common Stock, par value $0.00010.4646,657.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row
ORBIMED ISRAEL GP II, L.P. Common Stock, par value $0.00010.4646,657.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row
ORBIMED ISRAEL GP LTD. Common Stock, par value $0.00010.71,027,885.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP Common Stock, par value $0.00010.71,027,885.0010/08/2025 Filed 2025-10-10SCHEDULE 13D/AAmendment 8Open filing 0000947871-25-000897 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,686,506 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,124

Filings made before the SEC required XML are listed, not extracted.

Back to Adicet Bio, Inc.